The latest price target for Cellectis (NASDAQ:CLLS) was reported by Barclays on November 5, 2024. The analyst firm set a price target for $5.00 expecting CLLS to rise to within 12 months (a possible 155.10% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Cellectis (NASDAQ:CLLS) was provided by Barclays, and Cellectis maintained their overweight rating.

The last upgrade for Cellectis SA happened on May 18, 2022 when Baird raised their price target to N/A. Baird previously had a neutral for Cellectis SA.

The last downgrade for Cellectis SA happened on January 6, 2022 when Wells Fargo changed their price target from N/A to $16 for Cellectis SA.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a maintained with a price target of $7.00 to $5.00. The current price Cellectis (CLLS) is trading at is $1.96, which is out of the analyst’s predicted range.